FDA Approves Innoviva's Bacterial Pneumonia Treatment
May 23 2023 - 6:10PM
Dow Jones News
By Sabela Ojea
The Food and Drug Administration said Tuesday that it approved
Innoviva's Xacduro pneumonia treatment, which fights the
Acinetobacter bacteria.
The federal regulator said Xacduro, which treats
ventilator-associated bacterial pneumonia and hospital-acquired
bacterial pneumonia, is hard to treat and poses a great threat to
human health.
The FDA granted approval of Xacduro, administered by intravenous
infusion, to Entasis Therapeutics, acquired by the pharma company
Innoviva last year.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
May 23, 2023 18:55 ET (22:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Apr 2024 to May 2024
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From May 2023 to May 2024